Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Retained Earnings (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Retained Earnings data on record, last reported at -$1.4 million in Q3 2025.

  • For Q3 2025, Retained Earnings rose 65.78% year-over-year to -$1.4 million; the TTM value through Sep 2025 reached -$1.4 million, up 65.78%, while the annual FY2024 figure was -$1.5 billion, 32638.13% down from the prior year.
  • Retained Earnings reached -$1.4 million in Q3 2025 per SGMO's latest filing, up from -$1.6 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at -$1.4 million in Q3 2025 and bottomed at -$1.6 billion in Q2 2025.
  • Average Retained Earnings over 5 years is -$676.1 million, with a median of -$871.1 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: crashed 52597.1% in 2021, then soared 99.43% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$956.3 million in 2021, then soared by 99.12% to -$8.4 million in 2022, then surged by 45.32% to -$4.6 million in 2023, then plummeted by 32638.13% to -$1.5 billion in 2024, then soared by 99.9% to -$1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$1.4 million in Q3 2025, -$1.6 billion in Q2 2025, and -$1.5 billion in Q1 2025.